JPMorgan Chase & Co. Buys Shares of 99,690 Drugs Made In America Acquisition Corp. $DMAA

Key Points

• JPMorgan Chase & Co. bought a new stake of 99,690 shares (~$1.02M) in Drugs Made In America Acquisition, owning about 0.34% of the company at quarter-end.
• Several institutions also moved into or expanded positions—most notably Karpus Management (2,744,109 shares, ~ $27.99M) and Wolverine Asset Management (1,249,128 shares, ~ $12.83M), with Boothbay, Shaolin and Radcliffe also initiating or adding stakes.
• Analyst sentiment is negative: Weiss Ratings reiterated a "sell (d-)" and MarketBeat shows a consensus "Sell," while DMAA shares trade around $10.52, near their 52-week high and recent moving averages.

JPMorgan Chase & Co. bought a new stake in Drugs Made In America Acquisition Corp. (NASDAQ:DMAA - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 99,690 shares of the company's stock, valued at approximately $1,024,000. JPMorgan Chase & Co. owned about 0.34% of Drugs Made In America Acquisition at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DMAA. Karpus Management Inc. grew its stake in Drugs Made In America Acquisition by 18.1% in the second quarter. Karpus Management Inc. now owns 2,744,109 shares of the company's stock valued at $27,990,000 after purchasing an additional 420,075 shares during the last quarter. Shaolin Capital Management LLC purchased a new position in Drugs Made In America Acquisition in the second quarter valued at about $1,020,000. Boothbay Fund Management LLC purchased a new position in Drugs Made In America Acquisition in the second quarter valued at about $5,814,000. Radcliffe Capital Management L.P. purchased a new position in Drugs Made In America Acquisition in the second quarter valued at about $1,293,000. Finally, Wolverine Asset Management LLC grew its stake in shares of Drugs Made In America Acquisition by 22.2% during the third quarter. Wolverine Asset Management LLC now owns 1,249,128 shares of the company's stock worth $12,829,000 after acquiring an additional 227,222 shares during the last quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Drugs Made In America Acquisition in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Drugs Made In America Acquisition presently has a consensus rating of "Sell".

Drugs Made In America Acquisition Stock Performance

Shares of DMAA stock opened at $10.52 on Friday. Drugs Made In America Acquisition Corp. has a fifty-two week low of $10.02 and a fifty-two week high of $10.52. The stock's 50-day simple moving average is $10.47 and its 200-day simple moving average is $10.39.

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp NASDAQ: DMAA is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company's stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.

Want to see what other hedge funds are holding DMAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Drugs Made In America Acquisition Corp. (NASDAQ:DMAA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.